{"id":13494,"date":"2011-01-11T08:37:35","date_gmt":"2011-01-11T13:37:35","guid":{"rendered":"http:\/\/asweetlife.org\/?p=13494"},"modified":"2015-12-28T08:48:36","modified_gmt":"2015-12-28T13:48:36","slug":"eli-lilly-and-boehringer-ingelheim-to-develop-and-market-new-diabetes-drugs","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=13494","title":{"rendered":"Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs"},"content":{"rendered":"

\"\"<\/a>Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents\u2014linagliptin and BI10773\u2014as well as Lilly’s two basal insulin analogues\u2014LY2605541 and LY2963016\u2014as well as the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody.<\/p>\n

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by Boehringer Ingelheim and being developed as an oral once-daily tablet for the treatment of Type 2 diabetes.\u00a0 It is currently under regulatory review in the U.S., Europe and Japan. Boehringer Ingelheim’s BI10773, a sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor, began enrollment in Phase III clinical trials last year. It belongs to a new, emerging class of diabetes compounds that block tubular reabsorption of glucose in the kidney.\u00a0Currently there are no SGLT-2 inhibitors approved for use.<\/p>\n

Lilly’s two basal insulin analogue candidates are expected to enter Phase III clinical testing in 2011. Lilly’s two basal insulin analogue candidates are LY2605541, a structurally novel basal insulin analogue, and LY2963016, a new insulin glargine product. The agreement also includes an option for Boehringer Ingelheim to co-develop and co-commercialize another Lilly diabetes molecule, an anti-TGF-beta monoclonal antibody, which is currently in Phase II of clinical testing in patients with diabetes with chronic kidney disease.<\/p>\n

The alliance will leverage the collective scientific expertise and business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from the growing global diabetes epidemic.<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents\u2014linagliptin and BI10773\u2014as well as Lilly’s two basal insulin analogues\u2014LY2605541 and LY2963016\u2014as well as the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody….<\/p>\n","protected":false},"author":131,"featured_media":29414,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1541],"tags":[],"yoast_head":"\nEli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Boehringer Ingelheim announced an agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=13494\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=13494\",\"url\":\"https:\/\/asweetlife.org\/?p=13494\",\"name\":\"Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13494#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13494#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Lilly-Boehringer-logo.jpg\",\"datePublished\":\"2011-01-11T13:37:35+00:00\",\"dateModified\":\"2015-12-28T13:48:36+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Eli Lilly and Boehringer Ingelheim announced an agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in development.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13494#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=13494\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=13494#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Lilly-Boehringer-logo.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Lilly-Boehringer-logo.jpg\",\"width\":206,\"height\":131,\"caption\":\"Lilly - Boehringer - logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=13494#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs","description":"Eli Lilly and Boehringer Ingelheim announced an agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=13494","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=13494","url":"https:\/\/asweetlife.org\/?p=13494","name":"Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=13494#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=13494#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Lilly-Boehringer-logo.jpg","datePublished":"2011-01-11T13:37:35+00:00","dateModified":"2015-12-28T13:48:36+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Eli Lilly and Boehringer Ingelheim announced an agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in development.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=13494#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=13494"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=13494#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Lilly-Boehringer-logo.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Lilly-Boehringer-logo.jpg","width":206,"height":131,"caption":"Lilly - Boehringer - logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=13494#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly and Boehringer Ingelheim to Develop and Market New Diabetes Drugs"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/13494"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13494"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/13494\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29414"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}